Advertisement

ADVERTISEMENT

Gina Tomaine

News
Post-Transplant Eprenetapopt Plus Azacitidine Maintenance Shows Promise in TP53-Mutant AML and MDS
08/18/2022
Findings from a phase 2 study show post-transplant maintenance therapy with eprenetapopt plus azacitidine has the potential to improve outcomes for patients with TP53-mutant AML and MDS.
Findings from a phase 2 study show post-transplant maintenance therapy with eprenetapopt plus azacitidine has the potential to improve outcomes for patients with TP53-mutant AML and MDS.
Findings from a phase 2 study...
08/18/2022
Oncology
News
Idasanutlin Added to Cytarabine Fails to Improve OS in Relapsed/Refractory AML: MIRROS Trial
08/10/2022
The addition of idasanutlin to cytarabine showed no improvement in OS or complete remission rates in patients with relapsed/refractory AML, according to results from the MIRROS trial.
The addition of idasanutlin to cytarabine showed no improvement in OS or complete remission rates in patients with relapsed/refractory AML, according to results from the MIRROS trial.
The addition of idasanutlin to...
08/10/2022
Oncology
News
ASCT Improved Overall Survival Among Older Patients With Peripheral T-Cell Lymphoma
01/13/2023
In patients aged
In patients aged
In patients aged
01/13/2023
Oncology
News
Ciltacabtagene Autoleucel Maintains Deep and Durable Responses in MM With Longer Follow-up: CARTITUDE-1
08/02/2022
Ciltacabtagene autoleucel yielded deep and durable responses in heavily pretreated patients with relapsed/refractory MM, which were maintained at a follow-up of 28 months, according to an updated analysis of the CARTITUDE-1 trial.
Ciltacabtagene autoleucel yielded deep and durable responses in heavily pretreated patients with relapsed/refractory MM, which were maintained at a follow-up of 28 months, according to an updated analysis of the CARTITUDE-1 trial.
Ciltacabtagene autoleucel...
08/02/2022
Oncology
News
Bevacizumab Biosimilar Demonstrates Efficacy, Acceptable Toxicity Compared to Reference Bevacizumab for Patients With Locally Advanced and Advanced NSCLC
06/16/2023
Bevacizumab biosimilar demonstrated comparable efficacy to reference bevacizumab among patients with locally advanced and advanced non-small-cell lung cancer, with an acceptable toxicity profile, according to a retrospective study.
Bevacizumab biosimilar demonstrated comparable efficacy to reference bevacizumab among patients with locally advanced and advanced non-small-cell lung cancer, with an acceptable toxicity profile, according to a retrospective study.
Bevacizumab biosimilar...
06/16/2023
Oncology
News
Chemotherapy Plus Ponatinib Followed by Transplant Well-Tolerated in Adults With Philadelphia–Positive ALL
10/18/2022
The combination of chemotherapy with ponatinib followed by alloHSCT is well-tolerated in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia, according to a phase 2 trial.
The combination of chemotherapy with ponatinib followed by alloHSCT is well-tolerated in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia, according to a phase 2 trial.
The combination of chemotherapy...
10/18/2022
Oncology
News
CPX-351 vs FLAG-Ida Treatment for Patients With Adverse Karyotype AML/High-Risk MDS
09/29/2023
The overall survival of younger patients with adverse risk AML/MDS was not significantly different between treatment with CPX-351 or FLAG-Ida, according to findings from the UK NCRI AML19 trial.
The overall survival of younger patients with adverse risk AML/MDS was not significantly different between treatment with CPX-351 or FLAG-Ida, according to findings from the UK NCRI AML19 trial.
The overall survival of younger...
09/29/2023
Oncology
News
Ruxolitinib Shows Promise as a Safe, Effective Treatment for Steroid-Refractory GVHD
08/10/2022
Ruxolitinib is a potentially effective and safe treatment for patients with steroid-refractory GVHD, according to findings from a systematic review and meta-analysis.
Ruxolitinib is a potentially effective and safe treatment for patients with steroid-refractory GVHD, according to findings from a systematic review and meta-analysis.
Ruxolitinib is a potentially...
08/10/2022
Oncology
News
Splenectomy Can Be Delayed in Transfusion-Dependent Thalassemia With Appropriate Chelation Therapy
09/22/2022
Findings from a 30-year single-institution analysis reveal splenectomy can be delayed with appropriate chelation therapy in patients with transfusion-dependent thalassemia.
Findings from a 30-year single-institution analysis reveal splenectomy can be delayed with appropriate chelation therapy in patients with transfusion-dependent thalassemia.
Findings from a 30-year...
09/22/2022
Oncology
News
Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide for ALL
09/20/2022
Busulfan plus cyclophosphamide demonstrated noninferior efficiency and safety compared with total body irradiation plus cyclophosphamide for adult patients with standard-risk B-cell ALL in a phase 3 trial.
Busulfan plus cyclophosphamide demonstrated noninferior efficiency and safety compared with total body irradiation plus cyclophosphamide for adult patients with standard-risk B-cell ALL in a phase 3 trial.
Busulfan plus cyclophosphamide...
09/20/2022
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD logo
December 9 ⁠–⁠ December 11
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use